Successful Advancement of Protein Hydrolysis-Based Fourth-Generation Dual Coating Technology
Cell Biotech announced on July 9 that it has successfully advanced its proprietary 'dual coating' technology and completed patent registrations for this technology in five countries: South Korea, Japan, China, the United States, and Europe.
According to Cell Biotech, this technological advancement has increased the survival rate of probiotics to as high as 91.6%. This was demonstrated through human application tests, showing that the intestinal survival rate is 221 times higher compared to conventional non-coated probiotics.
The fourth-generation dual coating technology, developed for the first time in the world by Cell Biotech, involves double-coating live probiotics with protein and polysaccharide. This protects the probiotics from human physiological environments such as gastric acid and bile acid and ensures their safe delivery to the intestines. The technology utilizes the body's unique pH differences: the robust coating remains intact in the stomach, while it naturally dissolves in the intestines to activate the probiotics. In this latest advancement, the protein used in the coating is hydrolyzed into smaller molecules, thereby enhancing the survival of the probiotics.
Cell Biotech derived optimal conditions for each CBT probiotic strain through cultivation and freeze-drying experiments based on the degree of protein hydrolysis. The company then scientifically validated the effectiveness of the technology through accelerated stability, acid resistance, and bile resistance tests, comparing coated and non-coated strains.
According to the experimental results, the survival rates were 85.2% in the 'accelerated stability' test (which checks product quality within the shelf life), 90.7% in the 'acid resistance' test under gastric acid conditions, and 91.6% in the 'bile resistance' test under bile acid conditions. These results confirm both the stability and efficacy of the technology.
Additionally, in a human application trial jointly conducted by Cell Biotech and Sahmyook Medical Center, the dual-coated probiotics showed up to 221 times higher intestinal survival rates compared to non-coated probiotics. In a randomized, double-blind clinical trial involving 40 adult men and women, the intestinal survival rates of all strains increased by an average of 100 times, and the CBT-LR5 strain showed a 221-fold increase. The advanced dual coating technology is currently applied to all Duolac products.
A Cell Biotech representative stated, "Many people mistakenly believe that the guaranteed number of probiotics refers to the number that survives to reach the intestines, but in fact, it only indicates the number of live bacteria in the product until the expiration date and is unrelated to intestinal survival. The key to ensuring probiotics survive to reach the intestines is the coating technology used. Cell Biotech continues to advance its world-first, fourth-generation probiotic coating technology, dual coating."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
